JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145

Benzinga · 1d ago
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $146 to $145.